Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Other Non-Current Assets: 2019-2024

Historic Other Non-Current Assets for Revolution Medicines (RVMD) over the last 6 years, with Dec 2024 value amounting to $12.1 million.

  • Revolution Medicines' Other Non-Current Assets rose 64.00% to $16.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.9 million, marking a year-over-year increase of 64.00%. This contributed to the annual value of $12.1 million for FY2024, which is 72.47% up from last year.
  • Revolution Medicines' Other Non-Current Assets amounted to $12.1 million in FY2024, which was up 72.47% from $7.0 million recorded in FY2023.
  • Over the past 5 years, Revolution Medicines' Other Non-Current Assets peaked at $12.1 million during FY2024, and registered a low of $1.1 million during FY2020.
  • For the 3-year period, Revolution Medicines' Other Non-Current Assets averaged around $7.3 million, with its median value being $7.0 million (2023).
  • In the last 5 years, Revolution Medicines' Other Non-Current Assets crashed by 57.76% in 2020 and then spiked by 146.13% in 2023.
  • Revolution Medicines' Other Non-Current Assets (Yearly) stood at $1.1 million in 2020, then soared by 60.24% to $1.7 million in 2021, then surged by 64.48% to $2.9 million in 2022, then soared by 146.13% to $7.0 million in 2023, then surged by 72.47% to $12.1 million in 2024.